Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 72 articles:
HTML format
Text format



Single Articles


    October 2017
  1. THALER J, Sigel C, Beasley MB, Wisnivesky J, et al
    Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
    Br J Cancer. 2017;117:1392-1395.
    PubMed     Text format     Abstract available


  2. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Text format     Abstract available


  3. NI Z, Yao C, Zhu X, Gong C, et al
    Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  4. VAHL JM, Friedrich J, Mittler S, Trump S, et al
    Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
    Br J Cancer. 2017 Oct 10. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  5. GABASA M, Ikemori R, Hilberg F, Reguart N, et al
    Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Br J Cancer. 2017;117:1128-1138.
    PubMed     Text format     Abstract available


    September 2017
  6. GREYSTOKE A, Steele N, Arkenau HT, Blackhall F, et al
    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Br J Cancer. 2017;117:938-946.
    PubMed     Text format     Abstract available


  7. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  8. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Text format     Abstract available


    August 2017
  9. LI M, Yang J, Zhou W, Ren Y, et al
    Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  10. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  11. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  12. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  13. ALEXANDER M, Wolfe R, Ball D, Conron M, et al
    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  14. WINTHER-LARSEN A, Demuth C, Fledelius J, Madsen AT, et al
    Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  15. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available


  16. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  17. CHERNYAVSKIY P, Edmondson EF, Weil MM, Little MP, et al
    High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice.
    Br J Cancer. 2017;117:41-50.
    PubMed     Text format     Abstract available


  18. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available


  19. BARRERA L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, et al
    CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  20. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Text format     Abstract available


    May 2017
  21. KAZDAL D, Harms A, Endris V, Penzel R, et al
    Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  23. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  24. MURUGANANDAN S, Alfonso H, Franklin P, Shilkin K, et al
    Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
    Br J Cancer. 2017;116:703-708.
    PubMed     Text format     Abstract available


  25. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


  26. HOLDENRIEDER S, Wehnl B, Hettwer K, Simon K, et al
    Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  27. PRUITT SL, Laccetti AL, Xuan L, Halm EA, et al
    Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.
    Br J Cancer. 2017 Feb 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  28. YANG JJ, Zhou Q, Yan HH, Zhang XC, et al
    A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  29. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  30. AL-KHAFAJI AS, Davies MP, Risk JM, Marcus MW, et al
    Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. WU YL, Sequist LV, Hu CP, Feng J, et al
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
    Br J Cancer. 2017;116:175-185.
    PubMed     Text format     Abstract available


  32. FAIVRE C, El Cheikh R, Barbolosi D, Barlesi F, et al
    Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients.
    Br J Cancer. 2017;116:344-348.
    PubMed     Text format     Abstract available


  33. NEAL RD, Barham A, Bongard E, Edwards RT, et al
    Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. KIM H, Sung JY, Park EK, Kho S, et al
    Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.
    Br J Cancer. 2017;116:370-381.
    PubMed     Text format     Abstract available


    November 2016
  35. GROSSI F, Rijavec E, Genova C, Barletta G, et al
    Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. CHEN HM, Tsai CM, Wu YC, Lin KC, et al
    Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  38. WALKER AJ, Baldwin DR, Card TR, Powell HA, et al
    Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.
    Br J Cancer. 2016 Nov 1. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    October 2016
  39. COURTIN A, Smyth T, Hearn K, Saini HK, et al
    Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
    Br J Cancer. 2016;115:1069-1077.
    PubMed     Text format     Abstract available


  40. ROBINSON LA, Jaing CJ, Campbell CP, Magliocco A, et al
    Reply to: Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  41. PONZETTO A, Figura N, Holton J
    Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    September 2016
  42. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. MALHOTRA J, Waterboer T, Pawlita M, Michel A, et al
    Serum biomarkers of polyomavirus infection and risk of lung cancer in never smokers.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  44. KOTSAKIS A, Matikas A, Koinis F, Kentepozidis N, et al
    A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
    Br J Cancer. 2016 Sep 8. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  45. EVISON M, Crosbie P, Navani N, Callister M, et al
    How should performance in EBUS mediastinal staging in lung cancer be measured?
    Br J Cancer. 2016 Aug 23. doi: 10.1038/bjc.2016.
    PubMed     Text format    


    July 2016
  46. BROUTIN S, Stewart A, Thavasu P, Paci A, et al
    Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer.
    Br J Cancer. 2016 Jul 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  47. ROBINSON LA, Jaing CJ, Campbell CP, Magliocco A, et al
    Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung.
    Br J Cancer. 2016 Jul 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  48. KARAGOUNIS IV, Kalamida D, Mitrakas A, Pouliliou S, et al
    Repression of the autophagic response sensitises lung cancer cells to radiation and chemotherapy.
    Br J Cancer. 2016 Jul 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  49. ZHANG H, Shao H, Golubovskaya VM, Chen H, et al
    Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. TANG R, Lei Y, Hu B, Yang J, et al
    WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. RENAUD S, Seitlinger J, Falcoz PE, Schaeffer M, et al
    Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  52. BENITEZ-MAJANO S, Fowler H, Maringe C, Di Girolamo C, et al
    Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  53. WALKER AJ, Baldwin DR, Card TR, Powell HA, et al
    Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.
    Br J Cancer. 2016 Jun 2. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  54. LUO J, Hendryx M, Qi L, Ho GY, et al
    Pre-existing diabetes and lung cancer prognosis.
    Br J Cancer. 2016 May 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    March 2016
  55. STEIN SM, James ES, Deng Y, Cong X, et al
    Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Br J Cancer. 2016;114:737-43.
    PubMed     Text format     Abstract available


  56. BOTZER LE, Maman S, Sagi-Assif O, Meshel T, et al
    Hexokinase 2 is a determinant of neuroblastoma metastasis.
    Br J Cancer. 2016;114:759-66.
    PubMed     Text format     Abstract available


  57. BYRNE NM, Nesbitt H, Ming L, McKeown SR, et al
    Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
    Br J Cancer. 2016;114:659-68.
    PubMed     Text format     Abstract available


  58. MARTIN P, Shiau CJ, Pasic M, Tsao M, et al
    Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.
    Br J Cancer. 2016;114:616-22.
    PubMed     Text format     Abstract available


  59. JIN Y, Wang J, Ye X, Su Y, et al
    Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
    Br J Cancer. 2016;114:532-44.
    PubMed     Text format     Abstract available


  60. KAO SC, Kirschner MB, Cooper WA, Tran T, et al
    A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
    Br J Cancer. 2016;114:524-31.
    PubMed     Text format     Abstract available


  61. TEBBUTT NC, Price TJ, Ferraro DA, Wong N, et al
    Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
    Br J Cancer. 2016;114:505-9.
    PubMed     Text format     Abstract available


    February 2016
  62. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    PubMed     Text format     Abstract available


    January 2016
  63. NISMAN B, Nechushtan H, Biran H, Peled N, et al
    New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer.
    Br J Cancer. 2016 Jan 26. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2015
  64. ZIELINSKI C, Lang I, Beslija S, Kahan Z, et al
    Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Br J Cancer. 2015 Dec 10. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  65. RENAUD S, Falcoz PE, Romain B, Olland A, et al
    Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.
    Br J Cancer. 2015;113:1637-8.
    PubMed     Text format    


    November 2015
  66. BAHLEDA R, Hollebecque A, Varga A, Gazzah A, et al
    Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
    Br J Cancer. 2015;113:1413-20.
    PubMed     Text format     Abstract available


  67. KUAN FC, Kuo LT, Chen MC, Yang CT, et al
    Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
    Br J Cancer. 2015;113:1519-28.
    PubMed     Text format     Abstract available


    October 2015
  68. RENAUD S, Falcoz PE, Schaeffer M, Guenot D, et al
    Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Br J Cancer. 2015;113:1206-15.
    PubMed     Text format     Abstract available


    September 2015
  69. ANDREEV K, Trufa ID, Siegemund R, Rieker R, et al
    Impaired T-bet-pSTAT1alpha and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma.
    Br J Cancer. 2015;113:902-13.
    PubMed     Text format     Abstract available


  70. CARDILLO G, Mokhles S, Williams N, Macbeth F, et al
    Comment on: 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.' Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy.
    Br J Cancer. 2015 Sep 15. doi: 10.1038/bjc.2015.
    PubMed     Text format    


  71. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


    July 2015
  72. DI BENEDETTO M, Toullec A, Buteau-Lozano H, Abdelkarim M, et al
    MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics.
    Br J Cancer. 2015 Jul 21. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: